ArticleCancers2021

Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients.

Kate Clancy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.